ABT 299

Known as: ABT-299 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-1998
02419941998

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a… (More)
Is this relevant?
1998
1998
Snapper, James R., Weixuan Lu, Peter L. Lefferts, and John S. Thabes. Effect of platelet-activating factorreceptor antagonism on… (More)
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
1997
1997
Objective and Design: ABT-299 is a prodrug that is converted by serum esterase to a potent platelet activating factor (PAF… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
1997
Review
1997
Platelet-activating factor (PAF), identified as 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, exhibits potent… (More)
Is this relevant?
1996
1996
ABT-299, a highly potent and selective platelet activating factor (PAF) antagonist, was found to be effective in rat models of… (More)
Is this relevant?
1996
1996
ABT-299 is an aqueous soluble prodrug that is converted rapidly in vivo to A-85783, a novel, highly potent, specific platelet… (More)
Is this relevant?
1996
1996
The role of platelet-activating factor (PAF) as a mediator of endotoxin-induced pathophysiology has been studied in several… (More)
Is this relevant?
1995
1995
 
Is this relevant?
1994
1994
Pyrrolothiazole 4 is a potent antagonist of platelet activating factor-mediated effects in a variety of in vitro and in vivo… (More)
Is this relevant?